Amid pressure from the White House, U.S. drug companies are experimenting with direct-to-consumer sales models that cut out the middlemen.

The pharmaceutical industry faces an innovation crisis with declining R&D productivity, rising costs, and regulatory challenges impacting drug development.

The global peptide and anticoagulant drugs market is witnessing significant growth, driven by factors such as the rising prevalence of cardiovascular diseases, technological advancements, and the ...

Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) ('Ligand”) announced today the pricing of $400.0 million aggregate ...

Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) ('Ligand”) announced today its intention to offer $400.0 million aggregate principal amount of convertible senior notes due 2030 (the 'notes”) in a ...

Serina Therapeutics, Inc. ("Serina") (NYSE American: SER), a clinical-stage biotechnology company advancing its lead IND candidate, SER-252, for advanced ...

Precigen's immunotherapy for a rare respiratory disease has become the first treatment to win U.S. regulatory approval for ...

A federal appeals court revived a lawsuit accusing Sanofi, Eli Lilly, Novo Nordisk, and AstraZeneca of conspiring to restrict ...

The EV-303 study is evaluating PADCEV ™ (enfortumab vedotin), a Nectin-4 directed antibody-drug conjugate, in combination with KEYTRUDA ™ (pembrolizumab), a PD-1 inhibitor, as neoadjuvant and adjuvant ...

$5 Million in Funding: In April 2025, Serina secured $5 million from strategic shareholders to support the continued development of SER-252 (POZ-apomorphine), Serina's lead clinical candidate for ...

The net proceeds from the offering were approximately $445.1 million, after deducting fees and expenses. Ligand used approximately $45.9 million of the net proceeds from the offering to pay the cost ...